Truist maintains Buy on National Health Investors, cuts target to $81
Truist Securities analyst Michael Lewis maintains a Buy rating on National Health Investors (NYSE: NHI) but lowers the price target from $89 to $81. The revision reflects a reassessment of the stock's valuation while keeping a positive outlook on the company's fundamentals.
*this image is generated using AI for illustrative purposes only.
Truist Securities analyst Michael Lewis has maintained a Buy rating on National Health Investors (NYSE: NHI) while adjusting the valuation outlook. The firm lowered the price target to $81, down from the previous target of $89. This revision reflects a reassessment of the stock's potential despite the continued positive stance on its performance.
Rating and Price Target Details
The decision to maintain the Buy rating indicates confidence in the company's fundamental strength and future prospects. However, the reduction in the price target suggests a more conservative view on the near-term upside.
| Metric | Value |
|---|---|
| Rating | Buy |
| Previous Price Target | $89 |
| New Price Target | $81 |
National Health Investors operates as a real estate investment trust (REIT) focused on financing healthcare infrastructure. The revised target provides investors with an updated benchmark for the stock's valuation based on current market conditions and company-specific factors.
What specific market conditions or company-specific factors prompted Truist to lower the price target?
How might the revised valuation impact investor sentiment toward National Health Investors in the short term?
What are the potential risks or opportunities for NHI given its focus on healthcare infrastructure financing?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
